Drug Repurposing Study Shows Promise for Alzheimer's

A comprehensive new review published in Ageing Research Reviews suggests that repurposing existing medications could revolutionize Alzheimer's disease treatment. As the global prevalence of Alzheimer's continues to climb—affecting over 55 million people worldwide with projections reaching 139 million by 2050—researchers are increasingly turning to drug repurposing as a promising alternative to traditional drug development approaches.

What This Study Found

The study by More and colleagues conducted an extensive analysis of drug repurposing strategies for Alzheimer's disease, examining how existing medications with established safety profiles could be redirected to address the complex, multifactorial nature of the condition. The researchers found that Alzheimer's disease is characterized by multiple pathological processes, including amyloid-β plaque deposition, tau hyperphosphorylation, synaptic dysfunction, neuroinflammation, and oxidative stress.

According to the research, current approved therapies such as cholinesterase inhibitors and NMDA receptor antagonists provide only symptomatic relief rather than addressing underlying disease mechanisms. The study suggests that recently approved anti-amyloid monoclonal antibodies have shown limited clinical efficacy while presenting significant safety and cost concerns.

The researchers identified several promising categories of repurposed drugs targeting different pathological pathways:

Antidiabetic agents including metformin and GLP-1 receptor agonists showed potential in addressing metabolic dysfunction associated with Alzheimer's progression. The study suggests these medications may help improve brain glucose metabolism and reduce inflammation.

Anti-hypertensive medications such as candesartan demonstrated neuroprotective properties beyond their primary cardiovascular effects. Researchers found these drugs may help maintain cerebral blood flow and reduce neuroinflammation.

Anti-inflammatory drugs including NSAIDs and pioglitazone were highlighted for their potential to address the neuroinflammatory component of Alzheimer's pathology.

Notably, the study emphasized mitochondrial dysfunction as a significant early factor in Alzheimer's development. The researchers identified mitochondria-targeted therapeutics like SS-31, Mdivi-1, MitoQ, DDQ, and SkQ1 as particularly promising disease-modifying options that could address this fundamental aspect of the condition.

Clinical Significance

The research suggests that drug repurposing offers several critical advantages over traditional drug development approaches for Alzheimer's disease. The study found that repurposed drugs have known safety profiles, which could significantly accelerate the timeline for bringing effective treatments to patients.

The researchers noted that the integration of artificial intelligence, multi-omics approaches, and precision medicine is enhancing drug repurposing strategies. This technological advancement suggests that future repurposing efforts may become more targeted and effective.

The study's emphasis on multi-target approaches is particularly significant. Rather than focusing on single pathways, the researchers suggest that combining repurposed therapies targeting different aspects of Alzheimer's pathology could provide more comprehensive treatment benefits.

The identification of mitochondrial dysfunction as a central early factor represents a paradigm shift in understanding Alzheimer's progression. The study suggests that addressing mitochondrial health through repurposed drugs could potentially slow or prevent disease progression rather than merely treating symptoms.

Current Access and Compliance Context

The study indicates that many of the identified repurposed drugs are already FDA-approved for other conditions, which could facilitate faster regulatory pathways for Alzheimer's applications. However, researchers noted that additional clinical trials specific to Alzheimer's disease would still be necessary to establish efficacy and optimal dosing protocols.

The research suggests that cost-effectiveness could be significantly improved through drug repurposing, as these medications typically have lower development costs compared to novel drug discovery. This could make treatments more accessible to the growing global population affected by Alzheimer's disease.

Regulatory considerations for repurposed drugs may involve new indication approvals, which the study suggests could be streamlined due to existing safety data. However, researchers emphasized that proper clinical validation remains essential for each specific application.

What Patients Should Know

The study provides important context for patients and families affected by Alzheimer's disease. While the research shows promise for repurposed drugs, the authors emphasize that these findings represent ongoing research rather than established clinical recommendations.

Patients should understand that the study suggests drug repurposing could offer hope for more effective treatments, but additional clinical trials are needed to confirm safety and efficacy for Alzheimer's applications. The research indicates that some repurposed drugs may work by addressing underlying disease mechanisms rather than just managing symptoms.

The study's findings on mitochondrial-targeted therapies suggest that future treatments may focus on preventing or slowing disease progression. However, researchers noted that these approaches are still in development and require further validation.

Patients considering any medication changes should consult with qualified healthcare providers who can evaluate individual circumstances and current research developments. The study emphasizes that personalized medicine approaches may become increasingly important in optimizing repurposed drug therapies.

The research suggests that early intervention with repurposed drugs targeting mitochondrial function could be particularly beneficial, but this approach requires careful medical supervision and monitoring.

Conclusion

This comprehensive review highlights the significant potential of drug repurposing in addressing the growing global challenge of Alzheimer's disease. The study suggests that combining established medications with novel technological approaches could provide faster, safer, and more cost-effective therapeutic options. While additional research is needed to fully validate these approaches, the findings offer hope for improved treatment outcomes.

For patients and families seeking expert guidance on current Alzheimer's treatment options and emerging therapies, consulting with qualified specialists is essential. Visit peptideassociation.org/find-a-doctor to connect with healthcare providers experienced in neurodegenerative disease management.

Medical Disclaimer: This content is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals regarding any medical conditions or treatment decisions.

Citation: More PS, Rangari SW, Lade SN, et al. Drug repurposing in Alzheimer's disease: Emerging therapeutic strategies and promising candidates. Ageing Res Rev. 2026;103113. doi:10.1016/j.arr.2026.103113